Search results
Showing 46 to 60 of 124 results for rheumatoid arthritis
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.
View recommendations for IPG663Show all sections
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.
View recommendations for IPG271Show all sections
Sections for IPG271
Evidence-based recommendations on lateral elbow resurfacing for arthritis. This involves inserting an implant into the 2 bones that form the joint at the outer part of the elbow, under general anaesthetic.
View recommendations for IPG705Show all sections
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
All forms of inflammatory arthritis have similar management strategies coordinated through a multidisciplinary team. Pharmacological...
Evidence-based recommendations on shoulder resurfacing arthroplasty. This involves reshaping the upper arm bone and placing an artificial shoulder joint onto it.
View recommendations for IPG354Show all sections
Sections for IPG354
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued [GID-TA10180]
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making